References

DNA vaccines: ready for prime time?

10.1038/nrg2432 · 2008 · External reference

Cancer DNA vaccines: current preclinical and clinical developments and future perspectives

10.1186/s13046-019-1154-7 · 2019 · External reference

First COVID-19 DNA vaccine approved, others in hot pursuit

10.1038/d41587-021-00023-5 · 2021 · External reference

DNA Vaccines: Developing New Strategies against Cancer

10.1155/2010/174378 · 2010 · External reference

Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines

10.1172/jci200422608 · 2004 · External reference

DNA Vaccination: Transfection and Activation of Dendritic Cells as Key Events for Immunity

10.1084/jem.189.1.169 · 1999 · External reference

Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization

10.1084/jem.188.6.1075 · 1998 · External reference

B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA

10.1080/2162402x.2023.2212550 · 2023 · External reference

The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells

10.1172/jci34224 · 2008 · External reference

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands

10.1186/1471-2172-10-43 · 2009 · External reference

Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model

10.1186/s40425-016-0189-y · 2016 · External reference

Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response

10.1038/mt.2015.215 · 2016 · External reference

Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance

10.3389/fimmu.2021.674048 · 2021 · External reference

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape

10.3389/fimmu.2021.679344 · 2021 · External reference

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

10.1172/jci0214364 · 2002 · External reference

Cancer immunotherapy with mRNA-transfected dendritic cells

10.1111/j.0105-2896.2004.00139.x · 2004 · External reference

Recent Advancement in mRNA Vaccine Development and Applications

10.3390/pharmaceutics15071972 · 2023 · External reference

The Pivotal Role of Chemical Modifications in mRNA Therapeutics

2022 · External reference

The role of lipid components in lipid nanoparticles for vaccines and gene therapy

10.1016/j.addr.2022.114416 · 2022 · External reference

Lipid nanoparticles for mRNA delivery

10.1038/s41578-021-00358-0 · 2021 · External reference

Humoral and cellular immune memory to four COVID-19 vaccines

10.1016/j.cell.2022.05.022 · 2022 · External reference

Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection

10.1038/s41541-024-00976-z · 2024 · External reference

Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses

10.1016/j.immuni.2021.11.001 · 2021 · External reference

Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine

10.1038/s41541-024-00865-5 · 2024 · External reference

Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA

10.1016/j.jconrel.2017.09.041 · 2017 · External reference

COVID-19 vaccines: modes of immune activation and future challenges

10.1038/s41577-021-00526-x · 2021 · External reference

Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models

10.1038/s41467-024-44830-1 · 2024 · External reference

Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters

10.1016/j.omtm.2023.101169 · 2024 · External reference

Advances in mRNA LNP-Based Cancer Vaccines: Mechanisms, Formulation Aspects, Challenges, and Future Directions

2024 · External reference

mRNA vaccine trafficking and resulting protein expression after intramuscular administration

10.1016/j.omtn.2023.102083 · 2024 · External reference

Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates

10.1016/j.omtn.2022.09.017 · 2022 · External reference

The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects

2024 · External reference

RNA recognition in toll-like receptor signaling

10.1016/j.sbi.2024.102913 · 2024 · External reference

DNA Sensing in the Innate Immune Response

10.1152/physiol.00022.2019 · 2020 · External reference

cGAS-STING, an important pathway in cancer immunotherapy

10.1186/s13045-020-00916-z · 2020 · External reference

Type I interferon and cancer

10.1111/imr.13272 · 2024 · External reference

Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression

10.1080/2162402x.2022.2054758 · 2022 · External reference

DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond

10.3390/vaccines11061016 · 2023 · External reference

DNA Vaccines: History, Molecular Mechanisms and Future Perspectives

10.1016/j.jmb.2023.168297 · 2023 · External reference

DNA vaccines against COVID-19: Perspectives and challenges

10.1016/j.lfs.2020.118919 · 2021 · External reference

Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids

10.1038/s41587-025-02556-5 · 2026 · External reference

In vivo delivery of plasmid DNA by lipid nanoparticles: the influence of ionizable cationic lipids on organ-selective gene expression

10.1039/d2bm00168c · 2022 · External reference

Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)

10.1016/j.vaccine.2005.07.074 · 2006 · External reference

Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects

2024 · External reference

Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines

10.1021/acsnano.0c02765 · 2020 · External reference

Tumor-targeted delivery of a STING agonist improves cancer immunotherapy

10.1073/pnas.2214278119 · 2022 · External reference

Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants

10.1126/sciadv.abq3500 · 2022 · External reference

B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines

10.18632/oncotarget.12178 · 2016 · External reference

PEG400-mediated nanocarriers improve the delivery and therapeutic efficiency of mRNA tumor vaccines

10.1016/j.cclet.2023.108755 · 2024 · External reference

DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice

2015 · External reference

Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice

10.1016/j.isci.2022.105324 · 2022 · External reference

Comparison of DNA vaccines with AddaS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2

10.1016/j.isci.2023.107120 · 2023 · External reference

The multifaceted biology of plasmacytoid dendritic cells

10.1038/nri3865 · 2015 · External reference

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

10.1136/jitc-2021-004198 · 2022 · External reference

IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies

10.3389/fimmu.2021.735133 · 2021 · External reference

Interferon-α as Antiviral and Antitumor Vaccine Adjuvants: Mechanisms of Action and Response Signature

10.1089/jir.2011.0077 · 2012 · External reference

IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use

10.1586/erv.11.9 · 2011 · External reference

Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer

10.1007/s12032-024-02326-4 · 2024 · External reference

STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer

10.1038/s41416-018-0188-5 · 2018 · External reference

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy

10.3390/jcm9103323 · 2020 · External reference

Delivery of STING agonists for cancer immunotherapy

10.1016/j.copbio.2024.103105 · 2024 · External reference

Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells

10.1158/2326-6066.cir-16-0374 · 2017 · External reference

The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer

10.1007/s00262-012-1363-9 · 2013 · External reference

Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells

10.1021/acs.molpharmaceut.2c00033 · 2022 · External reference

Protein is expressed in all major organs after intravenous infusion of mRNA-lipid nanoparticles in swine

10.1016/j.omtm.2024.101314 · 2024 · External reference